WO 2005/040128

## **CLAIMS**

1. A compound of formula (I):

$$R^{2b} \qquad R^{8} \qquad R^{9} \qquad \qquad R^{1}$$

$$R^{2a} \qquad X = V$$

$$R^{2a} \qquad X = V$$

PCT/EP2004/011964

5 wherein:

W represents N or CR<sup>10</sup> wherein R<sup>10</sup> represents hydrogen, halogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heterocyclyl; X represents N or CR<sup>11</sup> wherein R<sup>11</sup> represents hydrogen, halogen, optionally substituted

(1)

alkyl, optionally substituted aryl, or optionally substituted heterocyclyl;

10 Y represents N or CR<sup>12</sup> wherein R<sup>12</sup> represents hydrogen, halogen, CH<sub>3</sub> or CF<sub>3</sub>; Z represents O, S, SO or SO<sub>2</sub>;

R¹ represents CO₂R⁴, CONR⁵R⁶, CH₂CO₂H, optionally substituted SO₂alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, 2*H*-tetrazol-5-yl-methyl or optionally substituted heterocyclyl;

R<sup>2a</sup> and R<sup>2b</sup> independently represents hydrogen, halo, optionally substituted alkyl,

optionally substituted alkoxy, CN, SO<sub>2</sub>alkyl, SR<sup>5</sup>, NO<sub>2</sub>, optionally substituted aryl, CONR<sup>5</sup>R<sup>6</sup> or optionally substituted heteroaryl;

R<sup>x</sup> represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally substituted by a group independently selected from NR<sup>4</sup>, O and SO<sub>n</sub>, wherein n is 0, 1 or 2: or R<sup>x</sup> represents optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-heterocyclyl,

optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-bicyclic heterocyclyl or optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-aryl; R<sup>4</sup> represents hydrogen or an optionally substituted alkyl;

R<sup>5</sup> represents hydrogen or an optionally substituted alkyl;

R<sup>6</sup> represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO₂aryl, optionally substituted SO₂alkyl, optionally substituted

25 SO₂heteroaryl, CN, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>aryl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>heteroaryl or COR<sup>7</sup>;

R<sup>7</sup> represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

R<sup>8</sup> and R<sup>9</sup> are independently selected from hydrogen, fluorine or alkyl, or R<sup>8</sup> and R<sup>9</sup> together with the carbon to which they are attached form a cycloalkyl ring, optionally containing up to one heteroatom selected from O, S, NH or N-alkyl; wherein Q<sup>a</sup> and Q<sup>b</sup> are each independently selected from hydrogen, CH<sub>3</sub> and fluorine; or a derivative thereof.

35 2. A compound according to claim 1 wherein the five membered ring comprising W, X and Y is pyrrole or pyrazole.

WO 2005/040128 PCT/EP2004/011964

- 3. A compound according to claim 1 or claim 2 wherein R<sup>1</sup> is CO<sub>2</sub>H.
- 4. A compound according to claim 1 selected from the compounds of Examples 1 to 61 and derivatives thereof.

5

15

20

25

- 5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.
- 10 6. A compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for use as an active therapeutic substance.
  - 7. A compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors.
  - 8. A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors which comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof.
  - 9. A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof.
  - 10. Use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors.

30

11. Use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as inflammatory pain, neuropathic pain or visceral pain.